**Table 2: Perioperative and postoperative outcomes of 337 patients stratified according to antithrombotic therapy**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **All Patients**  **Median (IQR)**  **N=337** | **NT**  **Median (IQR)**  **N=203** | **AP**  **Median (IQR)**  **N=83** | **AC**  **Median (IQR)**  **N=51** | **p value** |
| ***Perioperative*** |  |  |  |  |  |
| **Specimen weight (g)** | **75 (41-220)** | **75 (45-180)** | **80 (49-230)** | **70 (41-220)** | **0.107** |
| **Enucleation time (min)** | **46 (15-120)** | **45 (15-93)** | **52 (32-120)** | **50 (18-110)** | **0.548** |
| **Enucleation efficiency (g/min)** | **1.58 (0.87-3.13)** | **1.58 (0.87-3.13)** | **1.57 (1-2.86)** | **1.47 (1-2.20)** | **0.115** |
| **Morcellation time (min)** | **15 (4-60)** | **15 (5-42)** | **18 (5-60)** | **13 (4-42)** | **0.168** |
| **Morcellation efficiency (g/min)** | **5 (1-8.08)** | **5 (2.8-8.08)** | **4.92 (1-8)** | **4.73 (1.47-7.44)** | **0.204** |
| ***Postoperative*** |  |  |  |  |  |
| **Prolonged catheterization n(%)** | **36 (10.7)** | **15 (7.4)** | **15 (18.1)** | **6 (11.8)** | **0.028** |
| **Clot retention n (%)** | **1 (0.3)** | **0** | **1 (1.2)** | **0** | **0.216** |
| **Hemoglobin decrease within 12 hours after surgery (perioperatively) (g/dL)** | **1.2 (0.2-3.3)** | **1.2 (0.2-3.3)** | **1.2 (0.4-2.5)** | **1.1 (0.5-3.1)** | **0.225** |
| **Hemoglobin decrease at 1-week postoperatively (g/dL)** | **1.1 (0.1-3.1)** | **1.1 (0.1-3.1)** | **1 (0.40-3)** | **1.1 (0.4-2.8)** | **0.545** |
| **Postoperative PSA (ng/dL)** | **0.6 (0.1-8.1)** | **0.5 (0.1-2.4)** | **0.4 (0.1-4.1)** | **0.43 (0.1-1.5)** | **0.125** |

*IQR: Inter Quantile Range, NT: Non-Treatment, AP: Antiplatelet therapy, AC:Anticoagulation therapy, PSA:Prostate specific antigen.*